Results 151 to 160 of about 2,315,187 (340)
KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression
Cholangiocarcinoma (CCA) driven by oncogenic KRAS depends on its continuous activation for tumor maintenance. Using a conditional KRAS model, the authors show that turning off KRAS triggers rapid tumor regression accompanied by immune cell infiltration and cytokine release. The findings uncover a KRAS–senescence–immune signaling axis and highlight KRAS
Youwei Qiao +9 more
wiley +1 more source
Matrix Metalloproteinase Inhibition in Melanoma. [PDF]
Zhang E, Thakur V, Bedogni B.
europepmc +1 more source
H. E. Wart, Henning BIRKEDAL-HANSENt
semanticscholar +1 more source
Overexpression of Urokinase by Plaque Macrophages Causes Histological Features of Plaque Rupture and Increases Vascular Matrix Metalloproteinase Activity in Aged Apolipoprotein E–Null Mice [PDF]
Jie Hu +8 more
openalex +1 more source
FSTL1 promotes glycolysis during chondrocyte fibrosis by triggering the HIF‐1 signaling pathway, which causes lactate to accumulate. The buildup of lactate leads to changes in histone lysine lactylation, which in turn enhances the expression of genes associated with fibrosis.
Feng Lu +12 more
wiley +1 more source
Characterization of a cis-regulatory element upstream of matrix metalloproteinase-9. [PDF]
Rangaraj A +5 more
europepmc +1 more source
Matrix metalloproteinase expression and activity in human airway smooth muscle cells [PDF]
Shona R. Elshaw +5 more
openalex +1 more source
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia +14 more
wiley +1 more source

